Karaca, Emine EsraOzdek, SengulOzmen, Mehmet CuneytDursun, AyhanYalcin, Nuriye Gokcen2019-07-272019-07-282019-07-272019-07-2820160271-36831460-2202https://dx.doi.org/10.3109/02713683.2015.1039652https://hdl.handle.net/20.500.12418/7584Purpose: To evaluate safety, efficacy and postoperative characteristics of polyacrylamide 1.5% ophthalmic viscosurgical device (OVD) left in anterior chamber during and at the end of combined phacoemulsification and pars plana vitrectomy surgery. Materials and Methods: This prospective study comprised 20 eyes that received combined phacoemulsification and pars plana vitrectomy performed by the same surgeon. Polyacrylamide 1.5% was left in anterior chamber at the end of the surgery. Preoperative and postoperative examinations (4, 12 and 24 hours; 14 days; 1 and 3 months) included measurement of intraocular pressure (IOP), central corneal thickness (CCT), endothelial cell density and assessment of any ocular adverse reactions. Results : Four of the 20 patients (20%) showed increased IOP at hours postoperatively and needed medical treatment for IOP control. There was no significant difference in IOP between the preoperative visit and postoperative 3 months (p>0.05). CCT measurements were similar between preoperative and postoperative visits (p>0.05). A mean endothelial cell density loss of 6.7% was observed at postoperative day 14, however there was no change after this visit. Conclusion: Polyacrylamide 1.5% is safe, well-tolerated and protective in eyes undergoing combined phacoemulsification and pars plana vitrectomy.en10.3109/02713683.2015.1039652info:eu-repo/semantics/closedAccessCombined cataract and pars plana vitrectomyintraocular pressureophthalmic viscosurgical devicepolyacrylamideviscoelasticArticle414506501261259682-s2.0-84939556715Q2WOS:000375400100010Q2